BioAtla Inc

BioAtla Inc a clinical stage biopharmaceutical company develops specific and selective antibodybased therapeutics for the treatment of solid tumor cancer Its lead product candidate is BA3011 a conditionally active biologic CAB antibodydrug conjugate ADC for soft tissue and bone sarcoma tumors nonsmall cell lung cancer NSCLC and ovarian cancer It also develops BA3021 a CAB ADC for multiple solid tumor types including NSCLC melanoma and ovarian cancer and BA3071 which is a CAB anticytotoxic Tlymphocyteassociated antigen 4 antibody for renal cell carcinoma NSCLC small cell lung cancer hepatocellular carcinoma melanoma bladder cancer gastric cancer and cervical cancer BioAtla Inc was founded in 2007 and is based in San Diego California